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Abstract
This paper is a literature review of various scientific research papers, exploring the recent scientific
advancement in the field of genetic engineering. The research presented is a foundational tool, building awareness
on the implications of CRISPR/ Cas9 technology. CRISPR/ Cas9 was first discovered through the study of
bacterial immune systems, fighting against viral infections. Manipulation of the Cas9 protein would eventually
lead to target specific, gene-altering medicines for human organisms. CRISPR/ Cas 9 technology has begun to
show promise as an effective treatment for certain monogenic disorders. Despite this, time is required before its
efficacy as a proven genetic treatment plan. Certain drawbacks like chromosomal rearrangements and the
formation of cancerous cells, reveal the potential negative consequences of CRISPR/Cas9 treatment. Careful
calculations will be required to ensure the safety and specificity of this technology throughout future clinical
trials.
Keywords: CRISPR/ Cas 9, gene editing, genetic engineering, DNA mutation, non homologous end joining,
homologous directed repair, Intellia, CRISPR therapeutics, monogenic disorders
Evolution of Gene Therapy to Gene Editing
Gene therapy has been a growing field for
nearly 30 years. It has unbelievable potential to cure
genetic diseases, making it a hot topic of discussion.
Gene therapy generally refers to “gene transfer
therapy” a process of transferring a functioning copy of
a gene, a transgene, to the body. The transgene adds a
functioning version of the gene to make a healthy
protein (Kabadi, 2020). Genetic Therapy has proven to
be successful in various therapies; for example,
haematopoietic stem cell transfection has been used to
treat Cerebral Adrenoleukodystrophy (ALD) (Ridler,
2017). ALD is caused by a mutation which initiates
fatty acid breakdown, cerebral inflammation, and rapid
demyelination. Fortunately, the gene therapy
performed on 17 male ALD patients was “safe and
effective” (Ridler, 2017). While it introduces
astounding possibilities, the pursuit of gene therapy has
included tragic setbacks. An 18-year-old boy, Jesse

Gelsinger, enrolled in a gene therapy clinical trial for
an ornithine transcarbamylase (OTC) deficiency,
causing ammonia to accumulate in the blood.
Gelsinger was “infused with a corrective OTC gene, in
a dose of attenuated cold virus, a recombinant
adenoviral vector” that progressively caused organ
failure, leading to his death (Sibbald, 2001). After this
fatal event, gene therapy was fairly overlooked until
the discovery of zinc-finger nucleases (ZNF) and
transcriptor activator-like effector proteins (TALEN).
The utilization of proteins discovered from bacterial
defense mechanisms evolved gene therapy into geneediting. Gene-editing is different from gene therapy in
that editing works by correcting the faulty gene
through disruption, replacement, or correction. Both
ZNF and TALENs are made up of two parts: a binding
domain and a Fok1 endonuclease which cuts the
double-stranded
DNA
(Nemudryi,
2014).
Unfortunately, ZFNs and TALENS are time-
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consuming, bioengineers have to specifically program
individual proteins to recognize single DNA
nucleotides, whereas the CRISPR/ Cas9 system
“eliminates the need for elaborate protein engineering”
through the utilization of gRNA (Hong, 2018). Crispr’s
utilization of gRNA to locate specific DNA, and
mechanisms of the CRISPR protein to cut DNA, may
have long lasting implications on the bodies defense
response to genetic mutations.
What is Gene-Editing?
CRISPR gene-editing was first uncovered in
2012, by studying microbial defense systems, how
bacterial immune systems fight against viral infections
through the use of a Cas protein (Wu, 2020). From this
discovery, a CRISPR/ Cas9 complex was developed
and has been meticulously studied for the usage of
human genome editing (Zhang 2021). CRISPR/ Cas
complexes have been organized into three major Cas
systems followed by a wide variety of subtypes inside
of those systems (Makarova, 2011). CRISPR/Cas 9 is
considered to be a type II CRISPR system that
“requires only one protein (Cas9) for the recognition
and cleavage of a DNA site” (Makarova, 2011). The
Cas9 protein contains an endonuclease that cleaves or
cuts at a specific site. A spacer made of about 2-4 base
nucleotides, called protospacer adjacent motif (PAM),
is used to hold a specific place on the DNA (Barrangou
& Doudna, 2016). The Cas9 protein binds to a guide
RNA (gRNA), which directs the Cas9 protein to the
PAM recognition sequence. Once the gRNA
determines a match to the DNA nucleotides, a
cleavage, or a cut is induced on the double-stranded
DNA (Wu, 2020). The Cas9 protein in combination
with a gRNA and PAM complex essentially forms a
pair of molecular scissors. This is revolutionary
because CRISPR Cas 9 nuclease technology can be
used to either disrupt, replace, or correct mutated DNA
(Zhang, 2021).
After the slicing and dicing process has been
completed, cells have the ability to detect broken DNA,
initiating a cell’s repair response. The two major
methods for repair in the CRISPR/ Cas 9 complex are
non-homologous end joining (NHEJ) and Homologous
Directed Recombination Repair (HDR) (Humbert,
2021). Non-homologous end joining (NHEJ) describes
the body’s natural repair process, which simply
reattaches the broken ends of DNA. If correctly

repaired, this pathway can be harnessed to “knockout”
or silence an undesirable gene mutation (Uddin, 2020).
The drawback of this repair pathway is that certain
errors can occur from unintended insertions or
deletions called INDELS (Nemudryi, 2014). INDELS
essentially cause a frameshift which influences the way
a three codon DNA sequence is read. If the frame is
shifted by one nucleotide, it will cause an incorrect
amino acid sequence, resulting in abnormal proteins
(Education,
n.d.).
Homologous
Directed
Recombination Repair (HDR), is a method that has
significantly intrigued the scientific community
because it requires the insertion or “knock-in” of a new
genetically engineered template at the cleaved coding
site. HDR is a process which has never been achievable
historically, it eliminates the body's natural DNA repair
process to insert desirable genetic coding.
What is CRISPR/Cas 9 being used for?
By harnessing the power of the Cas9 protein,
leading scientists Jennifer Doudna along with
collaborator Emmanuelle Charpentier along with a
group of various scientists, discovered they could
utilize CRISPR/Cas9 protein complex to potentially
cure genetic diseases. Since their initial breakthrough
discovery of CRISPR technology in 2012, they have
since founded their own companies Intellia and
CRISPR Therapeutics. It should be noted, there are a
multitude of venture pharmaceutical companies that
have been formed surrounding CRISPR. This
technology will be tested on various genetic diseases,
yet for the purpose of simplicity this review will focus
on monogenic blood disorders. By following the
industry application of this scientific breakthrough, we
can begin to track the implication of this technology
and its effects on monogenic disorders in humans.
Intellia: Partnered with Regeneron and Novartis:
June 27, 2021, the first-ever clinical data from human
trials have been recorded on the effects of gene editing.
Specifically, Intellia’s NTLA-2001 intravenous
infusion is designed to prevent the unfolding of
transthyretin protein to treat amyloidosis, a protein
buildup that can interfere with the body's organ
functions (Leonard, 2021). ATTR is a monogenic
disorder, meaning only one gene has been affected,
making it an ideal candidate for CRISPR/ Cas9
“knockout” repair method (Gillmore et al., 2021).
Intellia, currently in the first phases of their clinical
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trial, reports that a single high dose of NTLA-2001 has
a 96% reduction in ATTR and a low dose has a 52%
reduction in ATTR (Gillmore et al., 2021). Further
tests are being done to determine the effects of
increased doses, so follow-up research will be
necessary as NTLA-2001 moves further into clinical
trials. Overall, from this research, we see a positive
effect from the usage of CRISPR/Cas9 “knockout”
method for the treatment of ATTR Amyloidosis.
Intellia’s additional gene-editing therapy for
hemoglobinopathy is currently in the first phases of
clinical trials. The therapies will be administered ex
vivo, meaning they will edit cells outside of the body,
to be delivered back in. Intellia plans to use
CRISPR/Cas9 editing to induce fetal hemoglobin
(HbF) expression, to treat Sickle Cell Disease (Hong,
2018). Sickle Cell Disease is a monogenic disorder that
causes misshapen red blood cells, interfering with the
delivery of oxygen throughout the body. The sickle cell
life span typically survives 10-20 days as opposed to a
healthy red blood cell’s 90-120 days (Mayoclinic,
2021). Typically, HbF is found only in infants, but
Intellia predicts they can edit this gene to activate in
fully grown adults, minimizing the negative effects of
genetic blood disorders. Further details on these trials
will be eagerly anticipated as the usage of
CRISPR/Cas9 continues to develop in human clinical
trials.
CRISPR Therapeutics partnered with Vertex
Therapeutics: Similarly, CRISPR Therapeutics has
begun clinical trials to treat hemoglobinopathies,
genetic blood disorders such as B-thalassemia, and
Sickle Cell Anemia. Traditional treatment for blood
disorders are transfusions, a procedure in which
donated blood is delivered into the body to replace old
blood cells (Mayoclinic, 2020). CRISPR Therapeutics
shares the same goal as Intellia, to treat blood disorders
by increasing fetal hemoglobin (HbF) levels. HbF is
oxygencarrying hemoglobin that is present in a fetus,
followed by rapid decline shortly after birth. If
CRISPR Therapeutics is successful, the activation of
HbF can alleviate pain symptoms and eliminate blood
transfusions. According to the New England Journal of
Medicine, early reportings of CTX001 show that fetal
Hemoglobin levels effectively rose in both a 19-yearold female patient with TDT and a 33 yr old female
with SCD, yet each patient also experienced adverse
health events (Frangoul, 2021). Specifically, the 19-

year-old experienced 32 adverse events, the most
severe being pneumonia and the 33-year-old
experienced 114 adverse events, the most severe being
sepsis (Frangoul, 2021). All conditions were monitored
and resolved with treatment, yet these early results
confess a need for further experimentation for
CRISPR/Cas9.
Victoria Gray is known as the first patient to
recieve CTX001 gene editing treatment for sickle cell
disease. Gray was treated in 2019 at the Sarah Cannon
Research Institute in Nashville, Tenessee. In an
exclusive interview with NPR news, Gray admitted
that sickle cell disease has put her through tremendous
pain, weakened her immune system, and damaged her
heart (Stein, 2021). Desperate to heal, she volunteered
for CRISPR/CAS9 DNA editing treatment to
reactivate fetal hemoglobin. In the most recent
interview on December 15, 2020, Victoria Gray has
claimed that “It's amazing! It's better than I could have
imagined. I feel like I can do what I want now.” Since
her treatment in 2019, she has not experienced severe
bouts of pain or emergency hospital visits (Stein,
2021). Further observation of her condition will
continue for years to determine the effectiveness of
CRISPR treatment in Sickle Cell Disorder.
Complications in Gene Editing
The major ongoing concern of CRISPR
systems, appears to be a question of specificity.
CRISPR/Cas 9 increases specificity, compared to ZNF
or TALENs. However, gRNA nucleases may induce
cuts on base pairs, at different locations other than the
intended sites. A knockout CRISPR/Cas9 study was
conducted on HBB gene, responsible for Bhemoglobin production, and CCR5 gene, an
attachment point for HIV. Substantial off-target
cleavage, resulting from edits on HBB and CCR5
genes, show large mismatches between gRNA and
complementary target sequences (Cradick, 2013). “A
high rate of off-target cleavage may result in large
indels, causing significant potential of mutagenesis and
chromosomal rearrangement” (Cradick, 2013).
Meaning, off-target edits may spawn undesirable
mutations in the human genome, an immense concern..
Furthermore, larger than expected deletions may have
pathogenic consequences (Kosicki, 2018). In an
attempt to prevent off-target edits, variants of the Cas9
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enzyme have been engineered, and continue to be
engineered, to detect and prevent unintended edits.
Supplemental complications with CRISPR/
Cas9 is the activation of p53 protein, which initiates the
cell’s repair systems to fix damaged DNA, causing
gene edits to be more challenging (Hong, 2018). Cells
without the p53 protein are more ideal candidates for
gene editing, yet p53 protein is necessary as a tumor
fighting cell response (Hong, 2018). It presents a
dilemma from which there is no escape, because of
mutually conflicting conditions. “Absence of p53 in
cells makes them more likely to become tumorous, as
DNA damage can no longer be corrected” (Hong,
2018). Increased cell populations, without the p53
pathway, will decrease the cell’s tumor-fighting
capability. The body's response to edits may result in
oncogenesis, the formation of cancerous cells. The
greatest shortcomings of gene editing is the body's
defense response to alterations, as well as, off-target
edits resulting in mutations. Meticulous steps are
required to ensure the safety of participants in clinical
trials.
Conclusion
The purpose of this paper is to explore the
CRISPR/Cas9 complex and the potential applications
for single-point mutations. Additionally, offer insight
into the pharmaceutical industry’s usage of gene
editing therapy in clinical trials. The CRISPR/Cas9 is
one of many variations of the CRISPR protein.
Modifications to the CRISPR protein have already
begun to take place in order to enhance specificity.
Further research is required to understand the full
implications of this technology as well as its effects on
patients. While the potential for this technology can be
life altering, negative consequences may take place in
the form of mutations or cancerous cells. A great deal
of observation of testing will be required to ensure the
safety of this groundbreaking technology.
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